US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

33.10

-0.2651-0.79%

Post-market: 33.100.00000.00%16:10 EST

Volume:57.27K

Turnover:1.90M

Market Cap:157.20M

PE:- -

High:33.73

Open:33.73

Low:33.02

Close:33.36

52wk High:34.00

52wk Low:25.63

Shares:4.75M

Float Shares:4.53M

Volume Ratio:0.40

T/O Rate:1.26%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns

Why Is Immunome Stock Soaring Monday?

Benzinga_recent_news

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Benzinga_recent_news

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

IPO Preview | Can Shima Pharma Win Market Favor in the Billion-Dollar TCE Oncology Therapy Blue Ocean?

Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Why Is Arcellx Stock Surging Today?

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":33.095,"timestamp":1766005200000,"preClose":33.3601,"halted":0,"volume":57267,"hourTrading":{"tag":"盘后","latestPrice":33.095,"preClose":33.095,"latestTime":"16:10 EST","volume":5,"amount":165.55,"timestamp":1766005804814},"delay":0,"floatShares":4530000,"shares":4750000,"eps":0,"marketStatus":"Post-Mkt","change":-0.2651,"latestTime":"12-17 17:50:10 EST","open":33.73,"high":33.73,"low":33.0229,"amount":1899776.9783,"amplitude":0.021196,"askPrice":33.25,"askSize":5,"bidPrice":33.05,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766019600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":33.3601,"sharesOutstanding":4750000,"nav":33.7,"aum":160075000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.095,"preClose":33.095,"latestTime":"16:10 EST","volume":5,"amount":165.55,"timestamp":1766005804814},"volumeRatio":0.404765},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":4530000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.404765,"shares":4750000,"dividePrice":0,"high":33.73,"amplitude":0.021196,"preClose":33.3601,"low":33.0229,"week52Low":25.63,"pbRate":"--","week52High":34,"institutionHeld":0,"latestPrice":33.095,"committee":-0.666667,"eps":0,"divideRate":0,"volume":57267,"delay":0,"ttmEps":0,"open":33.73,"prevYearClose":25.88,"prevWeekClose":33.4384,"prevMonthClose":33.5975,"prevQuarterClose":31.475,"fiveDayClose":33.5031,"twentyDayClose":32.59,"sixtyDayClose":31.9663},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131509857","title":"Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1131509857","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131509857?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:20","pubTimestamp":1765956051,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (referred to as \"Junshi Biosciences\") recently submitted its prospectus to the Hong Kong Stock Exchange. The company, a biotech firm focused on innovative cell...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","PFS","BK4585","BK4139","LU2487616109.SGD","ORR","BK4211","BK4505","BK4195","L","LU0053666078.USD","BK4107","LU0210528500.USD","BK4588"],"gpt_icon":0},{"id":"2591625183","title":"Why Is Immunome Stock Soaring Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625183","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591625183?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:12","pubTimestamp":1765818720,"startTime":"0","endTime":"0","summary":"Immunome stock surges after positive results from Phase 3 trial for desmoid tumors, meeting all key endpoints.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/15/Portrait-Of-A-Multiethnic-Student-Workin.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/15/Portrait-Of-A-Multiethnic-Student-Workin.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4563","IMNM","BK4139","ORR"],"gpt_icon":0},{"id":"2590043935","title":"Additional Confirmed Response Reported as Part of Amplia Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590043935","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590043935?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:45","pubTimestamp":1765547100,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Scienc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/12/3204647/0/en/Additional-Confirmed-Response-Reported-as-Part-of-Amplia-Investor-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INNMF","BK4139","ORR","PR","BK4213"],"gpt_icon":0},{"id":"2590597165","title":"InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2590597165","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590597165?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:03","pubTimestamp":1765450980,"startTime":"0","endTime":"0","summary":"BEIJING, Dec.  11, 2025  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (IC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203741/0/en/InnoCare-Announces-Approval-of-the-Next-Generation-TRK-Inhibitor-Zurletrectinib-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","PFS","OS","ORR","BK4211","BK4097","BK4195","NGS"],"gpt_icon":0},{"id":"2590326220","title":"Why Is Gene Therapy Focused Senti Bio Stock Falling Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590326220","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590326220?lang=en_us&edition=fundamental","pubTime":"2025-12-10 02:34","pubTimestamp":1765305240,"startTime":"0","endTime":"0","summary":"Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable remissions, and a favorable safety profile.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CR","ASH","SNTI","BK4109","ORR","BK4539","BK4161","LU2463526074.USD","BK4139"],"gpt_icon":0},{"id":"2590343065","title":"Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343065","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343065?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281600,"startTime":"0","endTime":"0","summary":"ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202225/0/en/Senti-Bio-Announces-Updated-SENTI-202-Clinical-Data-from-Ongoing-Phase-1-Trial-in-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-Patients-Demonstrating-Deep-MRD-Negative-Durable-Com.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","CR","BK4183","LD","BK4588","ORR","IE00BYQQ9H92.USD","BK4109","ODD","BK4533","MTD","BK4024","LU2463526074.USD","BK4548","IE00BFXG0V08.USD","LU1093756168.USD","BK4121","IE0009354923.USD","LU2413666699.HKD","ASH","AEI","LU0347712357.USD","LU2413666426.HKD","BK4563","LU1093756325.SGD","BK4161","LU2211817866.USD","BK4585","LU1721428933.USD"],"gpt_icon":0},{"id":"1152131178","title":"IPO Preview | Can Shima Pharma Win Market Favor in the Billion-Dollar TCE Oncology Therapy Blue Ocean?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152131178","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152131178?lang=en_us&edition=fundamental","pubTime":"2025-12-09 13:18","pubTimestamp":1765257530,"startTime":"0","endTime":"0","summary":"Recently, another innovative biopharmaceutical company officially submitted its IPO application to the Hong Kong Stock Exchange. According to disclosures, Zhejiang Shima Pharmaceutical Co., Ltd.-B...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","BK4107","CRS","BK4588","ADC","IE00B19Z4B17.USD","BK4187","LU0053666078.USD","BK4231","L","LU2487616109.SGD","LU0210528500.USD","ORR","LU0963586101.USD","IE0031619046.USD","LU2065731478.USD","BK4585","BK4080","IE00B7SZL793.SGD","BK4006"],"gpt_icon":0},{"id":"2590839528","title":"Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590839528","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590839528?lang=en_us&edition=fundamental","pubTime":"2025-12-09 10:04","pubTimestamp":1765245840,"startTime":"0","endTime":"0","summary":"BEIJING, Dec.  08, 2025  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202031/0/en/Latest-Data-of-InnoCare-s-Novel-BCL2-Inhibitor-Presented-at-the-67th-Annual-Meeting-of-the-American-Society-of-Hematology-ASH.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","LU1721428933.USD","BK4548","BK4117","BK4533","LU0347712357.USD","BK4588","LU2413666426.HKD","BK4211","LU2413666699.HKD","ORR","LU1093756168.USD","BK4107","LU1093756325.SGD","IE00BFXG0V08.USD","PB","BK4567","IE00BLDYK493.USD","LU2463526074.USD","IE00BYQQ9H92.USD","BK4585","BK4109","AFG","MTD","IE00B64QTZ34.USD","LU2211817866.USD","BK4121"],"gpt_icon":0},{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IE0031619046.USD","LU0963586101.USD","LU2065731478.USD","PFS","BK4109","BK4161","CR","BK4187","ASH","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4006","CRS","OS","ORR","LU2463526074.USD","BK4097","BK4211"],"gpt_icon":0},{"id":"2590368866","title":"Why Is Arcellx Stock Surging Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368866","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368866?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:23","pubTimestamp":1765218180,"startTime":"0","endTime":"0","summary":"Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU1430594728.SGD","IE00B7SZLL34.SGD","BK4139","BK4550","SG9999015945.SGD","BK4532","IE00B19Z3581.USD","BK4566","BK4588","IE0002270589.USD","LU1066051498.USD","SG9999015978.USD","PFS","BK4195","BK4583","LU1674673428.USD","SG9999015986.USD","GILD","LU0882574055.USD","BK4109","OS","IE00B19Z3B42.SGD","LU1571399168.USD","ASH","BK4211","LU2463526074.USD","LU1585245621.USD","LU0889565916.HKD","LU1839511570.USD","SG9999015952.SGD","LU0109394709.USD","BK4578","LU2087621335.USD","LU2089984988.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0114720955.EUR","LU0823416689.USD","LU1674673691.USD","ACLX","ORR","BK4097","LU1778281490.HKD","LU0234570918.USD","LU0289739699.SGD","LU0320765992.SGD","IE00B3T34201.USD","LU1066053197.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2589355106","title":"Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355106?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200900,"startTime":"0","endTime":"0","summary":"Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201559/0/en/Autolus-Therapeutics-Presents-Initial-Clinical-Data-in-Pediatric-r-r-B-ALL-Patients-and-Other-Oncology-Data-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","CRS","FC","BK4187","BK4123","BK4139","UCL","BK4007","BK4588","BK4006","BK4230","CR","IE00B7SZL793.SGD","BK4132","BK4109","OS","BK4117","LU1571399168.USD","ASH","IE00B66KJ199.SGD","LU2463526074.USD","ALL","IE00B19Z4B17.USD","LU0963586101.USD","CAR","IE0031619046.USD","BK4585","LU2355687059.USD","LENZ","AFG","LU0985320562.USD","ORR","BK4097","BK4022","LU2065731478.USD","BK4107","BK4161","BK4539","BK4533"],"gpt_icon":0},{"id":"2589533799","title":"Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533799","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533799?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194600,"startTime":"0","endTime":"0","summary":"– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute le","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201378/0/en/Syndax-Highlights-Leadership-in-Menin-Inhibition-at-ASH-2025-with-Multiple-Revuforj-revumenib-Presentations-Spanning-the-Acute-Leukemia-Treatment-Continuum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","ORR","LU0985320562.USD","ALL","BK4588","ASH","BK4097","BK4533","LU2355687059.USD","BK4109","ECG","BK4161","LU2463526074.USD","LU1571399168.USD","OS","BK4129","BK4107","HSCT","BK4585","CR"],"gpt_icon":0},{"id":"2589828533","title":"ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589828533?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:30","pubTimestamp":1765175400,"startTime":"0","endTime":"0","summary":"Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201199/0/en/ASH-2025-Cellectis-Presents-Development-Plan-to-Further-Enhance-High-Response-Rate-Observed-for-Eti-cel-in-r-r-NHL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU2463526074.USD","BK4109","BK4139","ORR","CR","CLLS","ASH"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","ORR","HR","LU2463526074.USD","AAPG","BK4139","BK4109","ASH","BK4225","OS","BK4203"],"gpt_icon":0},{"id":"2589802971","title":"RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802971","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802971?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:00","pubTimestamp":1765155600,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinibamong Asian patients.Results from 501 participants who self-identified as Asian in the MARIPOSA trial, showed those treated with amivantamab plus lazertinib had a 26 percent lower risk of death compared with osimertinib , based on a median follow-up of 38.7 months. MedianOSfor the combination was not yet reached compared with 38.4months for osimertinib . Survival projections suggest that amivantamab plus lazertinib could extend median OS to more than a year beyond that achieved with osimertinib. At three years, 61 percent of patients treated with the combination were alive compared with 53 percent of those receiving osimertinib. The survival advantage was maintained at 42 months, with survival rates of 59 percent and 46 percent,respec","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-delivers-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-benefit-for-asian-patients-with-egfr-mutated-non-small-cell-lung-cancer-in-the--302633939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689431.USD","LU0912757837.SGD","LU2592432038.USD","LU0203347892.USD","LU1929549753.HKD","BK4504","IE00B19Z3B42.SGD","LU0058720904.USD","IE00BJT1NW94.SGD","LU0466842654.USD","ORR.AU","LU0345769631.USD","OS","BK4585","LU0234572021.USD","LU1894683348.USD","LU0345770308.USD","BK4581","LU1261432733.SGD","LU2089984988.USD","IE00B19Z3581.USD","LU2602419157.SGD","IE00B1BXHZ80.USD","LU1267930813.SGD","JNJ","IE00BLSP4452.SGD","SEER","LU2468319806.SGD","LU2129689514.USD","PFS","LU0345770993.USD","LU1732799900.SGD","LU1162221912.USD","IE00B4R5TH58.HKD","LU1674673691.USD","BK7095","LU2505996509.AUD","BK4195","BK4534","IE00B3T34201.USD","BK4550","LU0098860793.USD","LU1066051225.USD","LU1074936037.SGD","LU2505996681.GBP","IE00B3PB1722.GBP","IE00BGHQF631.EUR","ORR","LU1778281490.HKD","BK4559"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4109","BK4124","BK4211","ALX","ASH","OS","BK4161","CR","BK4195","SMP","BK4097","BK4080","BK4213","LU2463526074.USD","PFS","ORR","PR"],"gpt_icon":0},{"id":"2589187279","title":"Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589187279","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589187279?lang=en_us&edition=fundamental","pubTime":"2025-12-07 20:50","pubTimestamp":1765111800,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201123/0/en/Genmab-Presents-Pivotal-Phase-3-Data-from-EPCORE-FL-1-Trial-Demonstrating-Clinical-Benefit-of-EPKINLY-epcoritamab-bysp-in-Combination-with-Rituximab-and-Lenalidomide-R2-in-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","ASH","BK4161","BK4195","LU2463526074.USD","ORR","PFS","CR","BK4109"],"gpt_icon":0},{"id":"2589066826","title":"Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589066826","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589066826?lang=en_us&edition=fundamental","pubTime":"2025-12-06 23:15","pubTimestamp":1765034100,"startTime":"0","endTime":"0","summary":"Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201070/0/en/Ascentage-Pharma-Presents-Pivotal-China-Registrational-Study-Data-for-Lisaftoclax-in-Oral-Report-at-2025-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HR","AAPG","ASH","BK4117","BK4109","ORR","BK4107","BK4139","AFG","BK4225","LU2463526074.USD","BK4203","BK4097","TLS"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905037.USD","ASH","BK4226","BK4161","LU0545562505.USD","CRS","BK4548","BK4106","BK4109","BK4187","BR","IPI","BK4097","LU2463526074.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2065731478.USD","BK4006","BK4093","IE0031619046.USD","BK4588","LU0390134368.USD","LU1228905540.USD","BK4211","BK4195","LU0963586101.USD","ORR","OS","IE0034235188.USD","PFS","IE0009354923.USD","CR","IE00B19Z4B17.USD","BK4585"],"gpt_icon":0},{"id":"2589841767","title":"Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841767?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990660,"startTime":"0","endTime":"0","summary":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201030/0/en/Toripalimab-Presents-Long-Term-Survival-Benefits-as-1st-line-Treatment-for-Advanced-Nasopharyngeal-Carcinoma-and-Esophageal-Squamous-Cell-Carcinoma-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","GP","AEIS","IE0031619046.USD","BK4006","BK4195","IE00B19Z4B17.USD","LU0054578231.USD","BK4149","LU1815336091.USD","BK4097","BK4211","LU0757428866.USD","LU0053671581.USD","IE00B7SZL793.SGD","BK4157","HCC","ITT","OS","RCC","IE00B66KJ199.SGD","PFS","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":141,"code":"91000000","status":"200"}]}}